Cocrystal Pharma, Inc. - COCP
About Gravity Analytica
Recent News
- 09.15.2025 - 8-K - Current report
- 09.15.2025 - Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- 09.15.2025 - Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- 09.15.2025 - 424B5 - Prospectus [Rule 424(b)(5)]
- 09.12.2025 - 8-K - Current report
- 09.12.2025 - 8-K - Current report
- 09.12.2025 - 424B3 - Prospectus [Rule 424(b)(3)]
- 09.12.2025 - Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- 09.12.2025 - Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- 09.12.2025 - Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference